Ovarian cancer is more likely to occur before and after menopause
When it comes to ovarian cancer, many women will smell it, and indeed, ovarian cancer is a common gynecological malignancy with a high incidence. At present, the incidence of ovarian cancer has accounted for 23%~27% of gynecological malignant tumors, becoming the fifth most common cancer in the world, and the mortality rate has jumped to the first among gynecological tumors. It can occur at any age in women, but it mostly occurs around the time of menopause, with about half occurring after the age of 65.
Because the location of the ovaries is deep in the pelvic cavity, in the early stage of cancer, the patient can not have any conscious symptoms, so it is not easy to attract attention, and it is not easy to take the initiative to carry out examinations.
Therefore, the 5-year survival rate of ovarian cancer patients is only 30%~50%. If women over the age of 30, especially those around the age of menopause, can have regular gynecological and pelvic ultrasound examinations, they can achieve early detection, early diagnosis, and timely and reasonable treatment, then the 5-year survival rate of ovarian cancer can reach more than 90%.
The main treatment for ovarian cancer is surgical resection, and postoperative chemotherapy is also very important, and it should also be combined with immunotherapy, radiotherapy, hormone therapy and traditional Chinese medicine. The effectiveness of chemotherapy and the length of survival of patients depend on whether the tumor is completely resected. Therefore, surgery should remove the tumor lesion to the maximum. For those tiny tumors and residual tumor cells that are not visible to the naked eye, postoperative chemotherapy is necessary.
At present, chemotherapy for ovarian cancer mostly adopts the method of early, adequate and multi-course after surgery, which is the best choice to improve the cure rate and prolong the survival time. Since the metastasis and spread of ovarian cancer is mainly based on extensive implantation in the pelvis, chemotherapy for ovarian cancer is often administered intraperitoneally in order to expose the tumor to more drugs.At present, "Tysol + Poldine" is used as the standard chemotherapy regimen for first-line ovarian cancer. Radiotherapy is an adjuvant therapy for ovarian cancer and is mainly used in some patients who do not respond to chemotherapy. Traditional Chinese medicine has a good effect on improving the immunity of patients. Although immunotherapy and gene therapy have certain efficacy, they have not yet been widely applied in clinical practice.